<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01616888</url>
  </required_header>
  <id_info>
    <org_study_id>KTT2</org_study_id>
    <nct_id>NCT01616888</nct_id>
  </id_info>
  <brief_title>Paclitaxel Eluting Balloon for SFA In-stent Restenosis</brief_title>
  <official_title>Rug Eluting Balloon With Paclitaxel for Treatment of In-stent Restenosis in Femoropopliteal Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and efficacy on the use of drug eluting
      balloon (DEB) with paclitaxel to treat in-stent restenosis in femoropopliteal arteries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral artery disease (PAD) in the lower extremities can cause claudication, pain in the
      legs or feet and slowly wounds that can affect patients' quality of life and increase the
      risk of leg amputation and death. Both conventional balloon angioplasty (CBA) alone and CBA
      plus bare metal stents are the current primary endovascular therapy to treat PAD. However,
      exaggerated neointimal hyperplasia leading to in-stent restenosis is associated with CBA.
      Paclitaxel coated balloons have been recognized to be safe and effective for the treatment of
      coronary in-stent restenosis, which the investigators hypothesize to be applicable in
      femoropopliteal cases.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target lesion patency at 6-month follow-up.</measure>
    <time_frame>6-month post index procedure</time_frame>
    <description>Patency of target lesion at 6-month follow-up based on duplex ultrasound.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical success up to 12 months post index procedure</measure>
    <time_frame>12 months post index procedure</time_frame>
    <description>Improvement on clinical evaluations including staging of PAD according to the Rutherford category, ABI at 1, 6, 12 months post procedure compared to baseline assessment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>In-stent Arterial Restenosis</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SFA angioplasty with In.Pact Admiral drug eluting balloon</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PTA with drug eluting balloon with paclitaxel</intervention_name>
    <description>Angioplasty with drug eluting balloon with paclitaxel on femoropopliteal arteries</description>
    <arm_group_label>Treatment arm</arm_group_label>
    <other_name>In.Pact Admiral by Medtronic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  chronic symptomatic lower limb ischemia defined as Rutherford categories 2, 3, 4 or 5

          -  in-stent restenosis or occlusion in SFA or PPA 20mm - 200mm

        Exclusion Criteria:

          -  participation in another investigational drug or device trial

          -  life expectancy less than 12 months

          -  acute ischemia and/or acute thrombosis of the SFA/PPA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kong Teng Tan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2012</study_first_submitted>
  <study_first_submitted_qc>June 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2012</study_first_posted>
  <last_update_submitted>December 5, 2014</last_update_submitted>
  <last_update_submitted_qc>December 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug eluting balloon with paclitaxel</keyword>
  <keyword>in stent restenosis</keyword>
  <keyword>femoropopliteal arteries</keyword>
  <keyword>angioplasty</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

